Biopharmaceutical company Praxis Precision Medicines, Inc. (PRAX) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for relutrigine, a sodium channel functional state modulator for pediatric use for the treatment of patients with SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs).
The BTD was granted based on the positive data from cohort 1 in the Phase 2 EMBOLD study, as well as 11-month data from the open-label extension (OLE) period of the trial.
The company said the EMBOLD cohort 2 pivotal trial is currently ongoing and continues to enroll, with topline results in the first half of 2026 with NDA filing to follow.
Praxis has recently initiated the EMERALD study investigating relutrigine broadly in DEEs.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.